Thyrocare Technologies Ltd
NSE:THYROCARE
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
559.95
985.8
|
Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one THYROCARE stock under the Base Case scenario is 585.36 INR. Compared to the current market price of 956.15 INR, Thyrocare Technologies Ltd is Overvalued by 39%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Thyrocare Technologies Ltd
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for THYROCARE cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Thyrocare Technologies Ltd
Balance Sheet Decomposition
Thyrocare Technologies Ltd
Current Assets | 2.8B |
Cash & Short-Term Investments | 1.5B |
Receivables | 434.7m |
Other Current Assets | 856.7m |
Non-Current Assets | 3.7B |
Long-Term Investments | 256.2m |
PP&E | 2B |
Intangibles | 1B |
Other Non-Current Assets | 313.2m |
Current Liabilities | 904.8m |
Accounts Payable | 401.1m |
Short-Term Debt | 106.9m |
Other Current Liabilities | 396.8m |
Non-Current Liabilities | 266.3m |
Long-Term Debt | 227.1m |
Other Non-Current Liabilities | 39.2m |
Earnings Waterfall
Thyrocare Technologies Ltd
Revenue
|
5.9B
INR
|
Cost of Revenue
|
-1.7B
INR
|
Gross Profit
|
4.2B
INR
|
Operating Expenses
|
-3.2B
INR
|
Operating Income
|
979.8m
INR
|
Other Expenses
|
-203.4m
INR
|
Net Income
|
776.4m
INR
|
Free Cash Flow Analysis
Thyrocare Technologies Ltd
INR | |
Free Cash Flow | INR |
THYROCARE Profitability Score
Profitability Due Diligence
Thyrocare Technologies Ltd's profitability score is 61/100. The higher the profitability score, the more profitable the company is.
Score
Thyrocare Technologies Ltd's profitability score is 61/100. The higher the profitability score, the more profitable the company is.
THYROCARE Solvency Score
Solvency Due Diligence
Thyrocare Technologies Ltd's solvency score is 90/100. The higher the solvency score, the more solvent the company is.
Score
Thyrocare Technologies Ltd's solvency score is 90/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
THYROCARE Price Targets Summary
Thyrocare Technologies Ltd
According to Wall Street analysts, the average 1-year price target for THYROCARE is 994.5 INR with a low forecast of 984.75 INR and a high forecast of 1 023.75 INR.
Dividends
Current shareholder yield for THYROCARE is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
THYROCARE Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Thyrocare Technologies Ltd. engages in provison of indepedent diagnostic and pathological laboratory services. The company is headquartered in Navi Mumbai, Maharashtra and currently employs 2,115 full-time employees. The company went IPO on 2016-05-09. The firm operates with a centralized processing laboratory (CPL) in Mumbai, India for esoteric tests, and regional processing laboratory in metro cities of India and other parts of Asia. The firm offers technologies, including Chemiluminescence Immunoassay (CLIA), Enzyme Linked Immunosorbent Assay (ELISA), High Performance Liquid Chromatography (HPLC), Capillary Electrophoresis (CE), Ion Selective Electrode (ISE), Fluorescence Flow Cytometry, Nephelometry, Photometry, Liquid Chromatography Mass Spectrometry (LC-MS), Inductively Coupled Plasma-Mass Spectrometry (ICP-MS) and Cytogenetics. The firm offers various kinds of tests, such as Aarogyam X, Aarogyam XL, Aarogyam 1.1, Aarogyam 1.2 and Covid Antibody GT. The company also offers Thyroxine (T4), Triiodothyronine (T3), Thyroid-stimulating hormone and Complete Vitamin Profile tests.
Contact
IPO
Employees
Officers
The intrinsic value of one THYROCARE stock under the Base Case scenario is 585.36 INR.
Compared to the current market price of 956.15 INR, Thyrocare Technologies Ltd is Overvalued by 39%.